Indian Bulk Drug Makers Gear Up for Ozempic Patent Expiry, Preparing to Tap $94 Billion Opportunity by 2035

Indian firms are preparing to supply the basic ingredient for generic versions of Novo Nordisk's weight-loss drugs, Ozempic and Wegovy, as patent protection expires in 2026 in several large markets. Local giants Dr Reddy's Laboratories and Macleods Pharmaceuticals are gearing up to make bulk drugs, while smaller firms are also anticipating a massive demand surge. Indian API makers will face intense price competition from Chinese companies, which control 80% of the global generic bulk drugs supply chain.